

In-depth cooperation cases: Spatial multi-omics collaboration helps publish Nature Genetics (IF: 30.8)

Transcriptome, proteome, metabolome, spatial transcriptome, spatial metabolome, single-cell transcriptome

A New Start:

Spatial multi-omics reveals new subtypes and new diagnosis and treatment systems for clear cell renal cell carcinoma

nature genetics

Article

Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression



Scan to read the full text

Received: 20 February 2023 Accepted: 10 January 2024 Published online: 15 February 2024 Check for updates

Junyi Hu 6 1,14, Shao-Gang Wang 1,14, Yaxin Hou 1,14, Zhaohui Chen 2,14, Lilong Liu 1, Ruizhi Li³, Nisha Li^{3,4}, Lijie Zhou⁵, Yu Yang⁶, Liping Wang⁷, Liang Wang², Xiong Yang², Yichen Lei⁸, Changqi Deng², Yang Li @ ¹, Zhiyao Deng¹, Yuhong Ding¹, Yingchun Kuang¹, Zhipeng Yao¹, Yang Xun¹, Fan Li¹, Heng Li¹, Jia Hu¹, Zheng Liu¹, Tao Wang¹, Yi Hao⁵, Xuanmao Jiao¹º, Wei Guan **©** ¹⊠, Zhen Tao © 11,12 , Shancheng Ren © 13 & Ke Chen © 1 <

Article Highlights

- The first large cohort study of clear cell renal cell carcinoma (ccRCC) integrating conventional multi-omics and spatial multi-omics;
- A new subtype of ccRCC, dedifferentiated clear cell subtype ccRCC (DC-CD-ccRCC) was proposed, which has unique immune, metabolic and clinical characteristics;
- A new molecular classification and treatment system for ccRCC was established, which provides high guidance value for the diagnosis, surgery and drug administration of renal cancer and even personalized precision medicine.

In-depth cooperation: OE Biotech is one of the author's signed units

¹Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ²Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ³Shanghai Luming Biotech, Shanghai, China. ⁴Shanghai OE Biotech, Shanghai, China. ⁵Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. ⁶Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. ⁷Department of Pathology, Baylor Scott & White Medical Center, Temple, TX, USA. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. ⁹Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ¹⁰Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Philadelphia, PA, USA. ¹¹Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Tianjin's Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China. 12 Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 13 Department of Urology, Second Affiliated Hospital of Naval Medical University, Shanghai, China. ¹⁴These authors contributed equally: Junyi Hu, Shao-Gang Wang, Yaxin Hou, Zhaohui Chen. 🖂 e-mail: deniskwan@gmail.com; ztao@tmu.edu.cn; renshancheng@gmail.com; shenke@hust.edu.cn